Drug Profile
Deferoxamine intranasal - Sanomune
Alternative Names: SAN-121Latest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator HealthPartners Research Foundation
- Developer Sanomune
- Class Hydroxamic acids; Small molecules
- Mechanism of Action Iron chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 20 Mar 2013 No development reported - Preclinical for Alzheimer's disease in USA (Intranasal)
- 30 Jun 2010 Sanomune has been acquired by DiaMedica
- 06 Mar 2009 Preclinical trials in Alzheimer's disease in USA (Intranasal)